<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Central nervous system acute lymphoblastic leukemia: role of natural killer cells</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2022-05-17">17 May 2022</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Liron</forename><surname>Frishman-Levy</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Oncology and the Cancer Research Center</orgName>
								<orgName type="laboratory">Childhood Leukemia Research Section</orgName>
								<orgName type="institution" key="instit1">Edmond and Lily Safra Children Hospital and Sheba Medical Center</orgName>
								<orgName type="institution" key="instit2">Tel Hashomer</orgName>
								<address>
									<settlement>Ramat Gan</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Human Molecular Genetics and Biochemistry</orgName>
								<orgName type="institution">Tel Aviv University</orgName>
								<address>
									<settlement>Tel Aviv</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Avishai</forename><surname>Shemesh</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">The Shraga Segal Department of Microbiology, Immunology and Genetics</orgName>
								<orgName type="department" key="dep2">Faculty of Health Sciences</orgName>
								<orgName type="institution" key="instit1">The National Institute for Biotechnology in the Negev</orgName>
								<orgName type="institution" key="instit2">Ben-Gurion University of the Negev</orgName>
								<address>
									<settlement>Beer Sheva</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Allan</forename><surname>Bar-Sinai</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Cell and Developmental Biology</orgName>
								<orgName type="institution" key="instit1">Alexander Silberman Institute of Life Sciences</orgName>
								<orgName type="institution" key="instit2">The Hebrew University of Jerusalem</orgName>
								<address>
									<settlement>Jerusalem</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chao</forename><surname>Ma</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Medicine and Stem Cell Institute</orgName>
								<orgName type="institution">University of Minnesota</orgName>
								<address>
									<settlement>Minneapolis</settlement>
									<region>MN</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zhenya</forename><surname>Ni</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Medicine and Stem Cell Institute</orgName>
								<orgName type="institution">University of Minnesota</orgName>
								<address>
									<settlement>Minneapolis</settlement>
									<region>MN</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Shahar</forename><surname>Frenkel</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Ocular Oncology Service</orgName>
								<orgName type="department" key="dep2">Department of Ophthalmology</orgName>
								<orgName type="institution">Hadassah-Hebrew University Medical Center</orgName>
								<address>
									<settlement>Jerusalem</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vera</forename><surname>Muench</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Pediatrics and Adolescent Medicine</orgName>
								<orgName type="institution">Ulm University Medical Center</orgName>
								<address>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hilke</forename><surname>Bruckmueller</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Pediatrics</orgName>
								<orgName type="institution">University Hospital Schleswig Holstein</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Vokuhl</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Pediatric Pathology</orgName>
								<orgName type="institution">University Hospital Schleswig Hostein</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Klaus-Michael</forename><surname>Debatin</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Pediatrics and Adolescent Medicine</orgName>
								<orgName type="institution">Ulm University Medical Center</orgName>
								<address>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cornelia</forename><surname>Eckert</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Pediatric Oncology/Hematology</orgName>
								<address>
									<settlement>Charit</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Stanulla</surname></persName>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Department of Pediatric Oncology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Schrappe</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Pediatrics</orgName>
								<orgName type="institution">University Hospital Schleswig Holstein</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kerry</forename><forename type="middle">S</forename><surname>Campbell</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">The Research Institute of Fox Chase Cancer Center</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>PA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ron</forename><surname>Loewenthal</surname></persName>
							<affiliation key="aff13">
								<orgName type="laboratory">Tissue Typing Laboratory and National Laboratory for Solid Organ Transplants</orgName>
								<orgName type="institution">Sheba Medical Center</orgName>
								<address>
									<settlement>Ramat Gan</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Denis</forename><forename type="middle">M</forename><surname>Schewe</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Pediatrics</orgName>
								<orgName type="institution">University Hospital Schleswig Holstein</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jacob</forename><surname>Hochman</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Cell and Developmental Biology</orgName>
								<orgName type="institution" key="instit1">Alexander Silberman Institute of Life Sciences</orgName>
								<orgName type="institution" key="instit2">The Hebrew University of Jerusalem</orgName>
								<address>
									<settlement>Jerusalem</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lueder</forename><forename type="middle">H</forename><surname>Meyer</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Pediatrics and Adolescent Medicine</orgName>
								<orgName type="institution">Ulm University Medical Center</orgName>
								<address>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dan</forename><surname>Kaufman</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Medicine and Stem Cell Institute</orgName>
								<orgName type="institution">University of Minnesota</orgName>
								<address>
									<settlement>Minneapolis</settlement>
									<region>MN</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gunnar</forename><surname>Cario</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Pediatrics</orgName>
								<orgName type="institution">University Hospital Schleswig Holstein</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Angel</forename><surname>Porgador</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">The Shraga Segal Department of Microbiology, Immunology and Genetics</orgName>
								<orgName type="department" key="dep2">Faculty of Health Sciences</orgName>
								<orgName type="institution" key="instit1">The National Institute for Biotechnology in the Negev</orgName>
								<orgName type="institution" key="instit2">Ben-Gurion University of the Negev</orgName>
								<address>
									<settlement>Beer Sheva</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Shai</forename><surname>Izraeli</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Oncology and the Cancer Research Center</orgName>
								<orgName type="laboratory">Childhood Leukemia Research Section</orgName>
								<orgName type="institution" key="instit1">Edmond and Lily Safra Children Hospital and Sheba Medical Center</orgName>
								<orgName type="institution" key="instit2">Tel Hashomer</orgName>
								<address>
									<settlement>Ramat Gan</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Human Molecular Genetics and Biochemistry</orgName>
								<orgName type="institution">Tel Aviv University</orgName>
								<address>
									<settlement>Tel Aviv</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="institution">Universit äts Medizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Central nervous system acute lymphoblastic leukemia: role of natural killer cells</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2022-05-17">17 May 2022</date>
						</imprint>
					</monogr>
					<idno type="MD5">EB7E2D183121C1D54645509A40090A2C</idno>
					<idno type="DOI">10.1182/blood-2014-08-595108</idno>
					<note type="submission">Submitted August 13, 2014; accepted March 17, 2015. Prepublished online as</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:18+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Increased IL-15 expression in leukemic lymphoblasts is associated with activation of NK cells.</s></p><p><s>• The CNS may be an immunologic sanctuary protecting lymphoblasts from NK-cell activity.</s></p><p><s>Central nervous system acute lymphoblastic leukemia (CNS-ALL) is a major clinical problem.</s><s>Prophylactic therapy is neurotoxic, and a third of the relapses involve the CNS.</s><s>Increased expression of interleukin 15 (IL-15) in leukemic blasts is associated with increased risk for CNS-ALL.</s><s>Using in vivo models for CNS leukemia caused by mouse T-ALL and human xenografts of ALL cells, we demonstrate that expression of IL-15 in leukemic cells is associated with the activation of natural killer (NK) cells.</s><s>This activation limits the outgrowth of leukemic cells in the periphery, but less in the CNS because NK cells are excluded from the CNS.</s><s>Depletion of NK cells in NOD/SCID mice enabled combined systemic and CNS leukemia of human pre-B-ALL.</s><s>The killing of human leukemia lymphoblasts by NK cells depended on the expression of the NKG2D receptor.</s><s>Analysis of bone marrow (BM) diagnostic samples derived from children with subsequent CNS-ALL revealed a significantly high expression of the NKG2D and NKp44 receptors.</s><s>We suggest that the CNS may be an immunologic sanctuary protected from NK-cell activity.</s><s>CNS prophylactic therapy may thus be needed with emerging NK cell-based therapies against hematopoietic malignancies.</s><s>(Blood.</s><s>2015;125(22):3420-3431)</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. <ref type="bibr" target="#b0">1</ref> Involvement of the central nervous system (CNS) by ALL is a major clinical problem.</s><s>]<ref type="bibr" target="#b13">[12]</ref><ref type="bibr" target="#b15">[13]</ref><ref type="bibr" target="#b17">[14]</ref><ref type="bibr" target="#b18">[15]</ref> Despite its clinical importance, little is known about the mechanisms that cause CNS leukemia. <ref type="bibr" target="#b19">16</ref></s><s>We previously reported the association between increased expression of interleukin-15 (IL-15) mRNA in ALL blasts and increased risk for CNS involvement. <ref type="bibr" target="#b20">17</ref></s><s>9]<ref type="bibr" target="#b23">[20]</ref><ref type="bibr" target="#b24">[21]</ref> Williams et al <ref type="bibr" target="#b25">22</ref> recently proposed that IL-15 enhances growth of leukemic cells in the growth factor-poor environment of the cerebrospinal fluid (CSF).</s><s>Overall, however, the biological role of IL-15 in CNS-ALL remains unclear.</s></p><p><s>IL-15 displays pleiotropic functions by acting on various immune cells including natural killer (NK) cells.</s><s>NK cells are a subset of lymphocytes of the innate immune system that play an important role in cancer immune surveillance through their capacity to recognize and kill transformed cells without prior sensitization.</s><s>NK cell-mediated cytotoxicity is regulated by the balance of signals transmitted by activating and inhibitory receptors on conjunction with a target cell. <ref type="bibr" target="#b26">23,</ref><ref type="bibr" target="#b27">24</ref></s><s>]<ref type="bibr" target="#b36">[33]</ref> Here, we describe experiments that demonstrate that NK-cell activation by leukemic cells expressing IL-15 can lead to control of residual disease in the periphery but to a lesser extent in the CNS because of a lack of NK-cell penetration into the brain.</s><s>This could explain the association between IL-15 expression and CNS relapses of ALL and, importantly, suggests the need for CNS-directed prophylaxis in emerging protocols of antileukemia therapies with NK cells.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head><p><s>Cells 018Z cells ("Results"), REH, Jurkat, and NALM6 cell lines were maintained in RPMI medium supplemented with 10% fetal calf serum.</s><s>T-25 cells <ref type="bibr" target="#b37">34,</ref><ref type="bibr" target="#b38">35</ref> were cultured in Dulbecco's modified Eagle medium medium supplemented with 10% heat-inactivated horse serum.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Constructs and generation of stable cell lines</head><p><s>The murine IL-15 construct, in which the signal peptide of IL-2 is fused to the mouse IL-15 cDNA, was obtained from Hugh Brady and subcloned into the pCEFL expression vector.</s><s>018Z cells stably expressing luciferase and cherry fluorescent proteins were generated by transduction with the Cherry 2A luciferase _pLNT/Sffv-MCS/ccdB provided by Dr Vaskar Saha.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In vivo models</head><p><s>Experiments were performed in specific pathogen-free units and were approved by the institutional animal experiments committees.</s><s>See "Results" for a detailed description of the experiments.</s><s>For imaging, mice were anesthetized with ketamine-xylazine or isoflurane and were intraperitoneally injected with 150 mg/kg D-luciferin (Promega).</s><s>Bioluminescent imaging (IVIS; Caliper Life Sciences) of anesthetized mice was performed 10 minutes thereafter.</s><s>A bioluminescent image was acquired for 1 minute with medium binning, analyzed with Living Image software version 4.2 (Caliper Life Science), and quantified using a region of interest set to total flux (photons per second) or average radiance (photons per second per centimeter squared).</s><s>All images were set to the same scale based on the negative controls (mice with phosphate-buffered saline [PBS] injection). <ref type="bibr" target="#b39">36</ref></s><s>istopathology and hematoxylin and eosin staining of formalin-fixed brain and eyes were performed by routine methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NK-cell depletion</head><p><s>NK cells were depleted by intraperitoneal injections of 50 mL rabbit anti-Asialo GM1 (Cedarlane Laboratories) 1 day before leukemia transplantation and then once every 5 days.</s><s>To ensure NK depletion, mice were monitored weekly for peripheral blood NK cells by flow cytometry using NKp46 antibody.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antibodies and fusion proteins</head><p><s>The antibodies used are as follows: Alexa647-conjugated anti-mouse CD335 (NKp46), eFluor450-conjugated anti-mouse CD69 (eBioscience), allophycocyanin (APC)/phycoerythrin (PE)-conjugated anti-human CD19, PE-conjugated anti-human CD14, fluorescein isothiocyanate (FITC)-conjugated anti-CD3, PE-conjugated anti-human CD45 (IQ Products), APC/PE/Pacific Blue -conjugated anti-human CD56, Pacific Blue-conjugated anti-human CD16, APC-conjugated anti-human CD314 (NKG2D), biotin-conjugated anti-mouse NKG2D, strepavidin-conjugated PE/APC, APC/PE-conjugated anti-mouse CD49b (DX5), APC/PE-conjugated anti-human CD336 (NKp44), BV421 mouse anti-human CD107a, PE antihuman HLA A/B/C (W6/32) 7-amino-actinomycin D (7-AAD) (BioLegend), purified mouse anti-human DNAM-1 (DX11), mouse anti-human NKG2D (#149810), mouse anti-human IL-15 monoclonal antibody (mAb; R&amp;D Systems), isotype control mouse immunoglobulin (Ig)G1, mouse anti-human MICA, mouse anti-human MICB, mouse anti-human ULBP2 mAb, APC-conjugated F (ab9)2 goat anti-human IgG, FITC-conjugated F(ab9)2 goat anti-human IgG, and APC-conjugated F(ab9)2 goat anti-mouse IgG (Jackson).</s><s>Antibodies used for human cell surface labeling are as follows: PE-CyE5-conjugated CD10 mAb and phycoerythrin-Texas red-conjugated CD19 mAb (Beckman Coulter).</s><s><ref type="bibr" target="#b43">[39]</ref> Flow cytometry 018Z cells were incubated on ice with various human Fc-fusion proteins (40 mg/mL) or labeled with anti-MICA, anti-MICB, or anti-ULBP2, washed, and stained with APC-or FITC-conjugated anti-human-IgG or with APC-or FITC-conjugated antimouse IgG.</s><s>For analysis of cells prepared from hematopoietic organs, red blood cell lysis was performed using red blood cell lysis buffer (BioLegend).</s><s>Brains were homogenized in PBS followed by separation on a 40% Percoll (GE Healthcare) gradient to eliminate residual fat tissue before staining.</s></p><p><s>To reduce FcgII/IIIR-mediated antibody binding, 1 mL of anti-mouse CD32/ CD16 (mouse BD Fc block) was added to all samples before staining.</s><s>Dead cells were excluded using 7-AAD staining.</s><s>Cells were analyzed on a Gallios flow cytometer (Beckman Coulter) or FACS Canto II (BD Biosciences), and data were analyzed using either Kaluza or FlowJo (Tree Star) software.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Isolation and culture of primary NK cells</head><p><s>Primary human NK cells were isolated from peripheral blood from healthy donors using a human NK-cell isolation kit, which is based on the negative selection approach (RosetteSep; STEMCELL Technologies).</s><s>Purity (.85-90%) was confirmed by flow cytometry, and cells were cultured with IL-2 (300 U/mL) in CellGro stem cell serum-free growth medium (CellGenix) supplemented with 10% heat inactivated human serum, 1 mM sodium pyruvate, 2 mM L-glutamine, minimum essential medium nonessential amino acids, 1% penicillin/streptomycin, and 10 mM HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid].</s><s>Following in vitro culture with IL-2, total non-NK-cell contamination level was ,5% with no CD3 1 cells.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>KIR and HLA genotyping</head><p><s>KIR genotyping was performed with the KIR Genotyping SSP Kit (Invitrogen).</s><s>HLA typing was performed using LUMINEX-TM technology and Immucor Transplant Diagnostic (Stamford, CT) kits to obtain HLA A*, B*, and C* loci typing at low/intermediate resolution.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cytotoxicity assays</head><p><s>Cytotoxic activity of primary human NK cells against ALL cells was tested in a 5-hour killing assay as previously described. <ref type="bibr" target="#b44">40</ref></s><s>For NKG2D blocking experiments, NK cells were preincubated for 1 hour at 4°C with 10 mg/mL anti-human NKG2D mAb (Clone 149810; R&amp;D Systems, Minneapolis, MN) or with isotype control.</s><s>7-AAD staining was applied to exclude dead cells.</s><s>The percentage of specific cytotoxicity was calculated as follows: (experimental killingspontaneous killing)/(maximum killingspontaneous killing) 3 100.</s></p><p><s>Quantification of NKG2D (KLRK1) and NKp44 (NCR2) receptor and ligand mRNA in ALL BM samples was done in the same set of patients originally used in the IL-15 report, <ref type="bibr" target="#b20">17</ref> except for 2 patients lacking additional material.</s><s>Informed consent was obtained, and the protocol was approved by local and central ethical committees.</s><s>All patients on ALL-Berlin Frankfurt Munster 2000 underwent diagnostic lumbar puncture and CSF examination at admission to the participating hospital, cranial magnetic resonance imaging, and inspection of the retina.</s><s>Only CNS 1 patients (no blasts in CSF cytospins) were included as CNS-negative controls.</s><s>In all but 1 sample (70% blasts), the specimens contained .90%</s><s>blasts.</s><s>The expression level of the succinate dehydrogenase complex subunit A (SDHA) gene was used to normalize for differences in input cDNA.</s><s>QuantiTect primer assays were used to measure mRNA abundance of the NKG2D (KLRK1), NKp44, and SDHA genes (Qiagen).</s><s>Melting curve analyses were performed to verify the amplification specificity.</s><s>Each sample was tested in duplicate.</s><s>The expression ratio was calculated as 2 n , where n was the C T value difference normalized by the C T difference of a calibrator sample.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Results of in vivo or in vitro experiments are shown by mean 6 standard error (SE) or standard deviation, respectively.</s><s>Data were analyzed using GraphPad Prism 5 software, and comparisons between groups were performed by paired or unpaired Student t test as appropriate.</s><s>P , .05 was considered statistically significant.</s><s>Comparison of NKG2D (KLRK1) and NKp44 expression between patient groups was performed applying the Mann-Whitney U test.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Expression of IL-15 in mouse T-25 T-cell lymphoblasts increases mice survival associated with clinical symptoms for CNS involvement and activation of NK cells</head><p><s>To test the hypothesis that increased expression of IL-15 will be associated with CNS leukemia, we used the T-cell leukemia/ lymphoma model described by Hochman et al. <ref type="bibr" target="#b45">41,</ref><ref type="bibr" target="#b46">42</ref> T-25 cells, not expressing endogenous IL-15, were transfected with an expression vector encoding murine IL-15 (designated T-25-IL15; supplemental Figure <ref type="figure" target="#fig_0">1</ref>, available on the Blood Web site) and transplanted intraperitoneally into BALB/c neonates.</s><s>Constitutive expression of IL-15 significantly enhanced the survival of mice (Figure <ref type="figure" target="#fig_0">1A</ref>).</s><s>Remarkably, mice injected with T-25-IL15 cells had pronounced clinical CNS symptoms (eg, ataxia, side walk, spin when held by the tail) not observed in control mice (Figure <ref type="figure" target="#fig_0">1B</ref>).</s><s>The most dramatic manifestation was ocular involvement that was observed only in mice injected with T-25-IL15 (Figure <ref type="figure" target="#fig_0">1C</ref>).</s><s>3]<ref type="bibr" target="#b48">[44]</ref> Lymphoblasts isolated from the eye continue to secrete the IL-15 protein (Figure <ref type="figure" target="#fig_0">1D</ref>).</s></p><p><s>Surprisingly, histopathology analysis of brains isolated from 25 mice (12 mice injected with T-25-IL15 cells and 13 control mice) close to their time of death revealed that both groups exhibited lymphoblastic infiltration of the subarachnoid space, indicating that IL-15 is not necessary for blast entry into the CNS (Figure <ref type="figure" target="#fig_0">1E-F</ref>).</s><s>We therefore hypothesized that the IL-15-expressing cells activated NK cells that reduced the aggressiveness of the systemic leukemia, allowing sufficient time for development of symptomatic CNS and ocular disease.</s><s>Consistent with this hypothesis, the percentage of peripheral activated blood NK cells (NKp46, CD69 positive) was increased significantly in mice transplanted with T-25-IL15 (Figure <ref type="figure" target="#fig_0">1G</ref>; supplemental Figure <ref type="figure" target="#fig_1">2</ref>)</s></p><p><s>Enhanced control of peripheral ALL but not CNS leukemia in NK-cell-proficient NOD/SCID mice compared with NK-cell-deficient NOD/SCID/IL2Rg-null mice</s></p><p><s>To study another model for human CNS leukemia with physiologic IL-15 levels, we obtained 018Z ALL cells derived from a B-cell precursor ALL of a child with suspected CNS involvement that died during induction chemotherapy.</s><s>These cells causes isolated CNS leukemia in NOD/SCID mice. <ref type="bibr" target="#b49">45</ref></s><s>To examine whether the 018Z-induced CNS phenotype is associated with NK cell activation, we used 2 strains of immune-deficient mice: NOD/SCID mice containing some functional NK cells <ref type="bibr" target="#b50">46</ref> and NOD/SCID/IL2Rg null (NSG), in which there are no NK cells. <ref type="bibr" target="#b51">47</ref></s><s>NOD/SCID and NSG mice were intravenously injected with 10 7 and 5 3 10 6 018Z cells, respectively, and killed on the appearance of clinical CNS symptoms or the development of severe clinical disease.</s><s>The median survival of the NOD/SCID mice was 80 days after transplantation, and 5 of 10 developed hind limbs paralysis or ataxia.</s><s>In contrast, all NSG mice developed hind limb paralysis 3 weeks after transplantation (Figure <ref type="figure" target="#fig_1">2A</ref>).</s><s>Histopathologic examination of brain sections showed subarachnoid CNS leukemia infiltration in both NOD/SCID and NSG mice (Figure <ref type="figure" target="#fig_1">2B</ref>).</s><s>Flow cytometry of human CD10 1 CD19 1 leukemic cells revealed significant involvement of BM, spleen, and blood in the NSG mice but not in the NOD/SCID mice (Figure <ref type="figure" target="#fig_1">2C</ref>).</s><s>Similarly, enlarged spleens were present in NSG but not in NOD/SCID mice (Figure <ref type="figure" target="#fig_1">2D</ref>).</s><s>Thus, 018Z cells cause isolated CNS leukemia in NOD/SCID mice but a more aggressive combined CNS and peripheral leukemia in the NK-deficient NSG mice.</s></p><p><s>To examine the general relevance of these observations, we analyzed the leukemic phenotypes of 2 primary ALL cell xenografts in the 2 mouse strains (supplemental Figure <ref type="figure" target="#fig_2">3</ref>).</s><s>For both samples, the peripheral leukemic load was significantly lower in NOD/SCID mice, whereas in both strains, there was substantial CNS infiltration.</s><s>To study the correlations with NK cells, we analyzed an additional 7 xenografts of primary ALLs in NOD/SCID mice, <ref type="bibr" target="#b52">48</ref> depicting combined CNS/ peripheral leukemia.</s><s>As shown in Figure <ref type="figure" target="#fig_2">3A</ref>, there was a positive correlation between the levels of IL-15 mRNA in the ALL blasts and the level of NK cells with 1 outlier (marked with a triangle in Figure <ref type="figure" target="#fig_2">3A</ref>), in which an increase in NK cells was observed despite the absence of IL-15 expression.</s><s>Interestingly, these ALL cells carried the t(1;19)(q23 p13) chromosomal translocation that is known to be associated with increased risk for CNS involvement. <ref type="bibr" target="#b53">49,</ref><ref type="bibr" target="#b54">50</ref></s><s>Increased NK cells (351 NK cells/10 5 splenic cells) were also observed in another t(1;19)(q23 p13) NOD/SCID xenograft with CNS leukemia (patient A in supplemental Figure <ref type="figure" target="#fig_2">3</ref>).</s><s>Thus, t(1;19)(q23 p13) may stimulate NK cells in an IL-15-independent manner.</s><s>Importantly, increased NK-cell counts were associated with decreased peripheral leukemia and increased CNS infiltration of xenografted leukemic cells in the NOD/SCID mice (Figure <ref type="figure" target="#fig_2">3B-D</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>018Z cells induced aggressive peripheral and CNS leukemia in NK-cell-depleted NOD/SCID mice</head><p><s>To study directly the hypothesis that the leukemia was confined to the CNS in NOD/SCID mice because of the activation of NK cells in the periphery, we injected 018Z cells expressing both mCherry and luciferase reporter genes into NK cell-depleted and nondepleted NOD/SCID mice.</s><s>NK-cell depletion was achieved by intraperitoneal injection of anti-Asialo GM1 twice a week.</s><s>As depicted in Figure <ref type="figure" target="#fig_3">4A</ref>, the percentage of NK cells after treatment with anti-Asialo GM1 was 0.5 6 0.1 compared with 8.5 6 1.2 in PBS-injected control mice.</s><s>NK cells remained depleted throughout the experiment.</s></p><p><s>Similar to the phenotype observed in NSG mice, NK cell-depleted NOD/SCID mice developed aggressive systemic disease characterized by reduced survival (Figure <ref type="figure" target="#fig_3">4B</ref>; P 5 .003,</s><s>log-rank test), substantial weight loss (Figure <ref type="figure" target="#fig_3">4C</ref>), and significant increase of leukemic blasts in the blood, BM, and brain (Figure <ref type="figure" target="#fig_3">4Di</ref>-Diii).</s><s>Bioluminescent imaging of mice 27 days after transplantation supported these findings (Figure <ref type="figure" target="#fig_3">4E-F</ref>).</s><s>Thus, the increased burden of leukemia in the absence of NK cells was associated with an aggressive combined BM and CNS phenotype.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Poor penetration of NK cells to the CNS in mice with CNS leukemia</head><p><s>Our hypothesis that NK cells regulate development of isolated CNS leukemia assumes that NK cells do not penetrate the CNS, even in the presence of CNS leukemia that may be associated with compromise of the blood-brain-CSF barrier.</s><s>We therefore injected NSG mice intravenously with 2 3 10 5 018Z McCherry/luciferase-labeled leukemic cells.</s><s>Six days later, mice received either PBS or 10 7 human peripheral blood NK cells (PBNK) intravenously.</s><s>Mice were followed by bioluminescent imaging at days 0, 7, 13, and 20 after NK treatment and euthanized at the time when the debilitating symptoms developed (supplemental Figure <ref type="figure" target="#fig_3">4</ref>).</s><s>Although mice that received this single dose of NK-cell treatment did have slower tumor progression, as quantified by bioluminescence (Figure <ref type="figure" target="#fig_4">5A</ref>), this did not translate to increased survival (Figure <ref type="figure" target="#fig_4">5B</ref>).</s><s>At the end of experiment, there was extensive infiltration of peripheral hematopoietic organs and of the CNS in both groups.</s><s>Analysis of NK-cell trafficking to specific tissues shows that human NK cells can be seen in the blood and peripheral tissues at day 14 after NK-cell treatment (Figure <ref type="figure" target="#fig_4">5C</ref>); however, no NK cells are seen in the CNS at day 14 or at the end of experiment when the mice became moribund (Figure <ref type="figure" target="#fig_4">5C-D)</ref>.</s></p><p><s>Taken together, the NK depletion experiment in NOD/SCID mice (Figure <ref type="figure" target="#fig_3">4</ref>) and the analysis of human NK-cell distribution in NSG mice (Figure <ref type="figure" target="#fig_4">5C</ref>) show that, although NK cells appear to mediate anti-ALL activity in the periphery, the lack of NK cells in the CNS demonstrates that this region remains a sanctuary against NK cellmediated activity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>B-cell precursor ALL cell line 018Z secretes endogenous IL-15 and is efficiently killed by primary NK cells via NK2GD</head><p><s>We next investigated the mechanisms of NK-cell activity on 018Z human leukemic cells.</s><s>Consistent with the previously reported association between IL-15 production by ALL cells and CNS involvement, <ref type="bibr" target="#b20">17,</ref><ref type="bibr" target="#b25">22</ref> 018Z secreted IL-15 (Figure <ref type="figure">6A</ref>).</s><s>As our previous in vivo results indicated that 018Z leukemia growth was regulated by murine NK cells, we performed a standard killing assay in which 018Z cells were prelabeled Figure <ref type="figure">6</ref>.</s><s>018Z cells are efficiently killed by primary NK cells through interaction with NKG2D receptors.</s><s>(A) IL-15 levels (enzyme-linked immunosorbent assay) in the medium of various ALL cell lines after overnight incubation at 37°C.</s><s>(B) 018Z and REH cells were incubated for 5 hours with human primary NK cells at various effector to target (E:T) ratios.</s><s>Specific killing of 018Z cells was significantly higher than that of REH cells for all E:T ratios.</s><s>*P , .001;</s><s>**P , .0001</s><s>(t test).</s><s>(C) HLA-A/B/C expression on REH (black line) and 018Z cells (dashed line).</s><s>(D) Binding of Fc-fusion proteins of NK receptors to 018Z cells.</s><s>018Z cells were incubated with various human Fc-fusion proteins of NK receptors followed by labeling with goat anti-hIgG (black line): (i) hNKG2D-Ig, (ii) mNKG2D-Ig, (iii) NKp44-Ig, (iv) hNKp46-Ig, (v) mNKp46-Ig, and (vi) NKp30-Ig.</s><s>Nonspecific binding was detected by staining with human Fcprotein (filled gray).</s><s>(vii) Expression of the hNKG2D ligands on 018Z cells.</s><s>Purified mouse anti MICA (black line), MICB (dotted), and ULBP2 (dashed), followed by labeled goat anti-mIgG (filled gray).</s><s>Results are representative of 3 independent experiments.</s><s>(E-F) Killing assay of 018Z cells by IL-2-activated human primary NK cells with or without blocking antibodies for NKG2D and DNAM-1, respectively.</s><s>Pretreatment of NK cells with blocking antibodies for NKG2D significantly reduced the killing of 018Z cells.</s><s>Values are shown as means 6 standard deviation of triplicates.</s><s>*P , .00001</s><s>(t test, no mAb or isotype control compared with anti-hNKG2D).</s></p><p><s>with carboxyfluorescein diacetate succinimidyl ester and incubated with IL-2-activated primary human NK cells.</s><s>Consistent with the mouse experiments, 018Z cells were efficiently killed by human NK cells relatively to the resistance of another B-cell precursor leukemia cell line (REH) that does not secrete IL-15 (Figure <ref type="figure">6B</ref>).</s><s>Thus, 018Z cells express IL-15 and are sensitive to NK cytotoxicity.</s><s>This sensitivity could not be explained by reduction in HLA expression, as 018Z and REH expressed similar levels of HLA class I (Figure <ref type="figure">6C</ref>).</s><s>As killer-cell immunoglobulin-like receptor (KIR)/ KIR-ligand disparity influences NK-cell lysis of leukemic cells, <ref type="bibr" target="#b55">51</ref> we genotyped the NK-cell donor and target cells.</s><s>KIR2DL1, KIR2DL2, and KIR2DL3 inhibitory receptors were expressed on the NK cells, whereas both 018Z and REH cells expressed ligands for KIR2DL1 (Cw*04 and Cw*06), and in addition, 018Z cells expressed HLA-Cw*07, a KIR2DL2/3 ligand (supplemental Figure <ref type="figure" target="#fig_4">5</ref>).</s><s>Thus, despite an increased expression of inhibitory ligands, 018Z cells were susceptible to killing by NK cells.</s><s>These results indicate that KIR/HLA mismatch is not a major factor contributing to the increased susceptibility of 018Z cells to cytotoxicity.</s></p><p><s>3]<ref type="bibr" target="#b58">[54]</ref><ref type="bibr" target="#b59">[55]</ref> Because some cellular ligands for NK receptors (NKRs) are yet unknown, we characterized their expression by 018Z cells using Fc-fusion proteins of NKRs. <ref type="bibr" target="#b44">40</ref></s><s>Flow cytometry was used to examine the binding of Fc-fusion proteins of human and mouse NKG2D, human NKp30, NKp44, and NKp46, and mouse LY94 (NKp46 homolog) to putative ligands on the surface of 018Z cells.</s><s>We found that 018Z cells express ligands recognized by both human and mouse NKG2D, as well as ligands for the human NKp44 receptor (Figure <ref type="figure">6Di</ref>-Dvi).</s><s>We further examined the expression of known specific human NKG2D ligands: MHC class І-related proteins A and B (MICA/MICB) and the UL16 binding protein 2 (ULBP2) on 018Z cells.</s><s>As shown in Figure <ref type="figure">6Dvii</ref>, 018Z cells express all 3 ligands, with the highest expression for ULBP2.</s><s>Interestingly, ULBP2 was reported to also be effectively recognized by mouse NKG2D, <ref type="bibr" target="#b36">33</ref> which could explain the in vivo sensitivity of 018Z to murine NK (Figure <ref type="figure" target="#fig_3">4</ref>).</s><s>As NKp44 is not expressed by murine NK, expression of ligands to NKp44 by 018Z did not contribute to its NK-mediated growth retardation in mice.</s><s>For the human NK scenario, because the human NK-resistant REH cell line (Figure <ref type="figure">6B</ref>) expressed cell surface ligands to NKp44 but a very low level of ligands to NKG2D (data not shown), we hypothesized that the higher sensitivity of 018Z to human NK cells was mediated by NKG2D.</s><s>Indeed, using blocking antibodies to NKG2D, we show that the killing of 018Z is primarily mediated by NKG2D (Figure <ref type="figure">6E</ref>).</s><s>The NEC2/DNAM-1 interaction was reported to be involved in the pathway of acute lymphoblastic leukemia cell recognition by NK cells. <ref type="bibr" target="#b60">56</ref></s><s>However, blocking the DNAM-1/PVRnectin-2 recognition did not affect the lysis of 018Z by NK (Figure <ref type="figure">6F</ref>).</s><s>Together, our experiments suggest that the increased sensitivity to lysis by NK of the IL-15-secreting 018Z is mediated by the NKG2D/NKG2D ligand interaction.</s></p><p><s>Expression of NK-cell receptors and ligands in primary pediatric ALL diagnostic BM samples and association with CNS leukemia</s></p><p><s>To further establish the role of NK cells, its relevance to childhood ALL, and its association with CNS leukemia, we first examined the mRNA expression of NKG2D (KLRK1) and NKp44 (NCR2) receptors in ALL BM samples originally used in the IL-15 report. <ref type="bibr" target="#b20">17</ref></s><s>Clinical and biological characteristics of the samples analyzed are shown in Table <ref type="table" target="#tab_0">1</ref>.</s><s>were significantly higher in CNS involving leukemia (P 5 .004</s><s>and P 5 .001,</s><s>respectively; Figure <ref type="figure" target="#fig_6">7B</ref>).</s><s>We then extended these findings to the protein level and tested the cell surface expression of NKG2D and NCR2 proteins in the immune cells within those primary ALL BM samples with additional material available (6 CNS-negative and 3 CNS-positive samples).</s><s>Although the NCR2 mRNA level significantly differed in primary ALL BM samples, we could not detect significant cell surface expression of the NCR2 protein in the subset analyzed.</s><s>In contrast, significant enhancement of cell surface expression of the NKG2D protein was observed in T, NKT, and NK cells in BM diagnostic samples from CNS-positive patients (Figure <ref type="figure" target="#fig_6">7C</ref>).</s><s>In accordance, the qPCR analysis of the mRNA of these specific samples manifested enhancement of KLRK1 mRNA and of IL-15 mRNA (Figure <ref type="figure" target="#fig_6">7D</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Expression of both</head><p><s>Enhanced expression of NKG2D ligands by pediatric B-ALL cells was previously reported, particularly for ULBP1 and ULBP3. <ref type="bibr" target="#b60">56</ref></s><s>We thus assessed mRNA expression levels of the specific NKG2D ligands in these ALL BM samples.</s><s>Interestingly, ULBP1 and ULBP3 mRNA expression levels were enhanced in the CNS-negative compared with the CNS-positive samples (Figure <ref type="figure" target="#fig_6">7D</ref>).</s><s>ULBP3, and to a lesser extent ULBP1, was shown to be secreted in exosomes and thus could facilitate inhibition of NKG2D-mediated NK function. <ref type="bibr" target="#b61">57,</ref><ref type="bibr" target="#b62">58</ref></s><s>We therefore analyzed ULBP1, ULBP2, and ULBP3 in the entire set of 68 diagnostic BM samples and calculated the (ULBP1 1 ULBP3/ULBP2) mRNA expression ratio for each ALL BM sample.</s><s>Figure <ref type="figure" target="#fig_6">7E</ref> clearly shows that the ratios in the CNS-negative group were significantly higher than the ratios in the CNS-positive and CNS relapse groups (note that the y-axis scale is logarithmic).</s><s>Thus, the high expression of the NKG2D receptor in infiltrating NK cells coupled with lower expression of inhibitory NKG2D ligands in the BM at the time of diagnosis of ALL correlated with CNS leukemia.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The occurrence of CNS leukemia is largely explained by neurotropism of lymphoblasts and the poor penetration of antileukemic drugs into the CNS.</s><s>Here we demonstrate that the CNS is also an immunologic sanctuary for ALL cells.</s></p><p><s>We sought a mechanistic explanation to our previously reported association between IL-15 expression in ALL blasts and the increased risk for CNS relapse of ALL. <ref type="bibr" target="#b20">17</ref> Consistent with the known regulation of NK cells by IL-15, <ref type="bibr" target="#b28">[25]</ref><ref type="bibr" target="#b29">[26]</ref><ref type="bibr" target="#b30">[27]</ref><ref type="bibr" target="#b31">[28]</ref><ref type="bibr" target="#b32">[29]</ref><ref type="bibr" target="#b33">[30]</ref> we observed that the expression of IL-15 in cell lines and in primary ALL cells was associated with activation of NK cells.</s><s>Our data suggest that NK cells do not directly regulate leukemic blast penetrance and survival in the CNS.</s><s>Rather, neurotropism is caused by endogenous properties of ALL cells.</s><s>For example, William et al <ref type="bibr" target="#b25">22</ref> suggested that IL-15 may be directly involved in the survival and proliferation of cells in the CNS.</s><s>Similarly, Krause et al <ref type="bibr" target="#b53">49</ref> showed that MERTK kinase may regulate the CNS tropism of t(1;19) ALL.</s><s>Our studies of mouse and human cell lines and primary ALL cells demonstrate that NK cells activated by IL-15 or other mechanisms <ref type="bibr" target="#b60">56,</ref><ref type="bibr" target="#b63">59</ref> inhibit systemic peripheral leukemia but fail to enter the brain and control the CNS leukemia.</s></p><p><s>Recently, there has been significant progress in NK cell-based therapies of acute leukemias.</s><s>7]<ref type="bibr" target="#b72">[68]</ref><ref type="bibr" target="#b73">[69]</ref><ref type="bibr" target="#b74">[70]</ref> Our findings may be important for emerging NK-based therapies of acute leukemias, suggesting the need for additional prophylactic CNS-directed therapy.</s></p><p><s>A role for autologous NK cells in ALL surveillance has been suggested by genetic studies indicating that possessing more NKactivating KIR genes reduces the risk of developing leukemia. <ref type="bibr" target="#b75">71</ref></s><s>nterestingly, increased NK sensitivity associated with increased NK ligand expression has been recently demonstrated in BCR-ABL1 ALLs, a leukemia that is highly associated with CNS involvement. <ref type="bibr" target="#b60">56</ref></s><s>ur mechanistic studies imply a major role for NKG2D in NK surveillance of endogenous ALL cells.</s><s>We observed increased mRNA and protein expression of NKG2D on NK cells from diagnostic BM of ALL patients with CNS involvement.</s><s>This increase may be caused by IL-15 or alternatively by reduction in the secretion of "decoy" ULBP ligands. <ref type="bibr" target="#b61">57,</ref><ref type="bibr" target="#b62">58</ref></s><s>his is the first report suggesting that NK-cell activity against ALL is excluded from the CNS, and it raises multiple questions.</s><s>For example, should CNS prophylaxis be added to leukemia therapeutic protocols with NK cells?</s><s>Can increased NKG2D and a lower ratio of ULBP1 1 ULBP3/ULBP2 expression in diagnostic BM be translated into biomarkers for CNS relapse and for sensitivity to autologous NK cells?</s><s>These and other questions emerging from our discoveries need to be tested in prospective clinical trials.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Constitutive expression of IL-15 in T-25 lymphoma cells increases survival of mice and is associated with clinical CNS symptoms.</s><s>(A) Kaplan-Meier survival curve of 7-day-old BALB/C mice injected with either T-25-IL15 (n 5 27) or T-25 cells (n 5 28) (P , .0001,</s><s>log-rank test).</s><s>(B) Kaplan-Meier curve depicting the accumulated rate of CNS symptoms.</s><s>Mice were monitored every day for clinical symptoms for CNS involvement including spin when held by tail, ataxia, and side-walk.</s><s>These symptoms were present only in the T-25-IL15 group.</s><s>(C) Representative picture of a T-25-IL15-injected mouse with ocular involvement.</s><s>Note the opacity of the left eye (arrow) caused by accumulation of lymphoma cells in the left anterior chamber.</s><s>(D) IL-15 secretion was measured by enzyme-linked immunosorbent assay in cells derived from the eyes of T-25-IL15-injected mice (n 5 2).</s><s>The T-25-injected mouse served as a control.</s><s>(E-F) Hematoxylin and eosin staining of brain sections derived from T-25-(upper) and T-25-IL15-injected mice (lower), showing infiltration of lymphoma cells in the subarachnoid space.</s><s>Histopathology analysis revealed that there was no difference in the number of mice with CNS involvement between both groups.</s><s>(G) T-25-IL15injected mice exhibited a significant increase in peripheral blood NK cells.</s><s>Values presented as means 6 SE (P 5 .01,</s><s>t test).</s></p></div></figDesc><graphic coords="2,216.45,66.84,324.69,422.08" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. 018Z human pre-B-ALL cells induce isolated CNS leukemia in NOD/SCID mice and combined CNS/peripheral leukemia in NSG mice.</s><s>(A) A Kaplan-Meier survival curve of NOD/SCID (n 5 10) and NSG (n 5 4) mice injected intravenously with 018Z cells (P 5 .001;</s><s>log-rank test).</s><s>(B) Representative hematoxylin and eosin staining of brain sections from NOD/SCID (lower; n 5 10) and NSG (upper; n 5 3) mice presenting leukemia infiltration in the subarachnoid space.</s><s>(C) Flow cytometry analysis of peripheral leukemia percentage in the (i) blood, (ii) BM, and (iii) spleen using antibodies for CD10 and CD19.</s><s>Values are means 6 SE (P , .0001;</s><s>unpaired t test).</s><s>(D) Representative pictures of spleens taken from (i) NSG or (ii) NOD/SCID mice.</s></p></div></figDesc><graphic coords="3,50.80,66.84,324.69,403.09" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Associations of NK-cell infiltration in spleens of human ALL-bearing NOD/SCID with levels of IL-15 mRNA expression and with leukemic infiltrates of CNS and peripheral organs.</s><s>(A) Linear regression analysis of splenic mouse NK cells (DX5-and NKG2D-positive cells per 10 5 splenic cells) as a function of IL-15 mRNA expression in infiltrating human ALL cells (determined by qRT-PCR, values normalized to b actin mRNA levels 72,73 ).</s><s>The outlier (gray triangle) is a xenograft from a patient with t(1;19)-positive ALL demonstrating significant NK-cell accumulation despite no IL-15 expression.</s><s>(B-D) Increasing splenic NK-cell recruitment is significantly associated with (B) increased infiltration of human ALL cells in the recipient's CNS and (C-D) lower systemic leukemia burden in spleen and peripheral blood (Spearman correlation).</s></p></div></figDesc><graphic coords="4,57.03,66.84,478.04,378.20" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Depletion of NK cells reduced survival of mice and enhanced peripheral and CNS leukemia.</s><s>NOD/SCID mice were intraperitoneally injected with either anti-Asialo GM1 (n 5 13) or sterile PBS (n 5 11) and then transplanted with 10 7 cells intravenously.</s><s>(A) Confirmation of NK depletion by flow cytometry analysis of peripheral NK cells in blood samples from mice injected with anti-Asialo GM1 compared with PBS controls (P , .0001).</s><s>(B) Kaplan-Meier survival curve depicting reduced survival of the NKcell-depleted mice (P 5 .003,</s><s>log-rank test).</s><s>(C) Reduced weight of NK-cell-depleted mice on the day of euthanasia (P 5 .0005,</s><s>t test).</s><s>(D) Flow cytometry analysis of 018Zcherry-positive cells in the (i) blood, (ii) BM, and (iii) brain.</s><s>Data presented are from 3 independent experiments.</s><s>Values are means 6 SE.</s><s>Statistical analysis was performed by t test.</s><s>(E) Bioluminescent imaging of mice 27 days after transplantation with 018Z cells expressing the luciferase reporter: NK-cell-depleted mice (left) and PBS-injected mice (right).</s><s>(F) Quantification of the images in E by Living Image Software.</s><s>The leukemic load is represented as counts per minute (CPM; P 5 .004,</s><s>t test).</s></p></div></figDesc><graphic coords="5,57.03,66.84,478.04,480.36" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5 .</head><label>5</label><figDesc><div><p><s>Figure 5.</s><s>In vivo antitumor responses by expanded human NK cells in the 018Z-engrafted NSG mouse model.</s><s>Mice were intravenously injected with 2 3 10 5 018Z tumor cells and imaged by bioluminescence after 6 days to confirm tumor establishment.</s><s>Then mice received either PBS (n 5 11 mice) or 1 3 10 7 human PBNK cells (n 5 12 mice) at day 0 with IL-2 and IL-15 daily for the first week and IL-2 every other day for 3 more weeks.</s><s>(A) Bioluminescent analyses indicate significant delay in tumor growth in mice treated with PBNK cells at days 7 and 20.</s><s>(B) Kaplan-Meier survival curve of NK cell-treated and control mice.</s><s>These survival data use 7 mice from the PBS-treated group and 8 mice from the PBNK cell-treated group.</s><s>(C) NKcell engraftment was evaluated by flow cytometry.</s><s>Mice blood, brain, BM, spleen, lung, and liver tissues were collected from 4 mice at day 14 after PBNK treatment.</s><s>NK-cell survival/engraftment was evaluated by flow cytometry for CD45 1 CD56 1 cells in the live cell population.</s><s>(D) Analysis of NK cells (CD45 1 CD56 1 cells) in the blood and CNS at the end of the experiment when the remaining animals became moribund (n 5 7 in each group).</s><s>These studies demonstrate lack of penetration of NK cells into the CNS with significantly decreased NK cells in the CNS compared with peripheral blood and tissues.</s><s>All statistical analyses were performed by the Mann-Whitney test in Prism 4.0.</s></p></div></figDesc><graphic coords="6,216.45,66.84,324.69,274.22" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head></head><label></label><figDesc><div><p><s>NKp44 and NKG2D was analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) of cDNAs derived from BM samples of patients who were (1) CNS negative at initial diagnosis with no CNS relapse (n 5 44); (2) CNS positive at initial diagnosis (n 5 21); and (3) CNS negative at initial diagnosis with subsequent CNS relapse (n 5 21).</s><s>As depicted in Figure 7A, expression levels of NKG2D (KLRK1) were associated with CNS leukemia (when comparing group CNS positive vs negative and CNS negative vs CNS negative with subsequent CNS relapse; P 5 .07 and P 5 .03,</s><s>respectively).</s><s>Similarly, expression levels of NKp44 (NCR2) in BM</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 7 .</head><label>7</label><figDesc><div><p><s>Figure 7. Expression of NKG2D and NKp44 receptors and ligands on NK cells and the association with CNS leukemia.</s><s>Box plots demonstrating the positive association between the expressions of (A) NKG2D/KLRK1 and (B) NKp44/NCR2, respectively, and CNS involvement in leukemia in the entire set of 86 primary BM samples.</s><s>(C) Geometric mean fluorescence intensity of human NKG2D protein expression on T cells (CD45 1 /CD3 1 /CD56 2 /CD19 2 ), natural killer T (NKT) cells (CD45 1 /CD3 1 /CD56 1 /CD19 2 ), NK cells (CD45 1 /CD3 2 /CD56 1 /CD19 2 ), and CD45 1 /CD3 2 /CD56 2 /CD19 1/2 cells in a subset of 6 CNS-negative and 3 CNS-positive primary BM samples.</s><s>(D) qRT-PCR of IL-15, NKG2D/KLRK1, MICA, MICB, ULBP1, ULBP2, and ULBP3 in the same set as C. mRNA values are normalized to SDHA expression.</s><s>(E) Association of (ULBP1 1 ULBP3/ULBP2) mRNA ratio and CNS involvement in leukemia in the entire set of BM samples.</s><s>Data shown were derived through qRT-PCR after reverse transcription using RNA of BM mononuclear cells at initial diagnosis.</s><s>The line within the box plots of A, B, and E corresponds to the median value, the star is the mean value, the box length is the interquartile range, and the lines emanating from the box (whiskers) extend to the smallest and largest observations; outliers are indicated.</s><s>a.u., arbitrary units.</s><s>Statistical analyses were done by applying the 2-tailed Student t-test.</s></p></div></figDesc><graphic coords="9,57.03,66.84,478.04,527.02" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="7,50.80,66.84,324.69,387.10" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Characteristics at initial diagnosis of 44 CNS-negative patients with acute lymphoblastic leukemia, 21 CNS-positive patients, and 21 patients subsequently relapsing with CNS involvement</s></p></div></figDesc><table><row><cell></cell><cell>CNS negative (n 5 44) (%)</cell><cell>CNS positive (n 5 21) (%)</cell><cell>CNS relapse (n 5 21) (%)</cell><cell>P*</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1 to ,10</cell><cell>28 (63.6)</cell><cell>14 (66.7)</cell><cell>14 (66.7)</cell><cell></cell></row><row><cell>$10</cell><cell>16 (36.4)</cell><cell>7 (36.3)</cell><cell>7 (36.3)</cell><cell>1.000</cell></row><row><cell>Sex</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>26 (59.1)</cell><cell>12 (57.1)</cell><cell>16 (76.2)</cell><cell></cell></row><row><cell>Female</cell><cell>18 (40.9)</cell><cell>9 (42.9)</cell><cell>5 (23.8)</cell><cell>.390</cell></row><row><cell>Presenting white blood cell count/mL</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>,10 000</cell><cell>7 (15.9)</cell><cell>3 (14.3)</cell><cell>6 (28.6)</cell><cell></cell></row><row><cell>10 000 to ,50 000</cell><cell>20 (45.4)</cell><cell>8 (38.1)</cell><cell>5 (23.8)</cell><cell></cell></row><row><cell>50 000 to ,100 000</cell><cell>9 (20.5)</cell><cell>4 (19.0)</cell><cell>4 (19.0)</cell><cell></cell></row><row><cell>$100 000</cell><cell>8 (18.2)</cell><cell>6 (28.6)</cell><cell>6 (28.6)</cell><cell>.636</cell></row><row><cell>Immunophenotype</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>B-precursor</cell><cell>44 (100.0)</cell><cell>21 (100.0)</cell><cell>18 (85.7)</cell><cell></cell></row><row><cell>T-ALL</cell><cell>0</cell><cell>0</cell><cell>3 (14.3)</cell><cell>.808</cell></row><row><cell>BCR/ABL</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>44 (100.0)</cell><cell>18 (85.6)</cell><cell>19 (90.4)</cell><cell>.104</cell></row><row><cell>Positive</cell><cell>0</cell><cell>1 (4.8)</cell><cell>2 (9.6)</cell><cell></cell></row><row><cell>Not known</cell><cell>0</cell><cell>2 (9.6)</cell><cell>0</cell><cell></cell></row><row><cell>ETV6/RUNX1</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>44 (100.0)</cell><cell>16 (76.2)</cell><cell>18 (85.7)</cell><cell>.01</cell></row><row><cell>Positive</cell><cell>0</cell><cell>4 (19.1)</cell><cell>2 (9.5)</cell><cell></cell></row><row><cell>Not known</cell><cell>0</cell><cell>1 (4.7)</cell><cell>1 (4.8)</cell><cell></cell></row><row><cell>MLL/AF4</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Positive</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell></cell></row><row><cell>Treatment group</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Standard risk</cell><cell>18 (41.0)</cell><cell>8 (38.1)</cell><cell>2 (9.5)</cell><cell></cell></row><row><cell>Intermediate risk</cell><cell>9 (20.4)</cell><cell>7 (33.3)</cell><cell>14 (66.7)</cell><cell></cell></row><row><cell>High risk</cell><cell>17 (38.6)</cell><cell>6 (28.6)</cell><cell>5 (23.8)</cell><cell>.007</cell></row><row><cell>*x 2 or Fisher's exact test.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">ETV6, ets variant 6; RUNX1, runt-related transcription factor 1.</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Downloaded from http://ashpublications.org/blood/article-pdf/125/22/3420/1386268/3420.pdf by guest on 17 May 2022</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The authors thank Profs Vaskar Saha and Hugh Brady for providing reagents; Birthe Fedders, Inna Muler, and Rivka Kalt for technical assistance; and Prof Ofer Mandelboim for advice.</s></p><p><s>This study was supported in part by the Israel Science Foundation 757/07 Bikura grant (to S.I. and J.H.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Conflict-of-interest disclosure: The authors declare no competing financial interests.</s></p><p><s>Correspondence: Shai Izraeli, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; e-mail: sizraeli@sheba.health.gov.il; and Angel Porgador, The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; e-mail: angel@bgu.ac.il.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Laningham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Kun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Reddick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Ogg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Pui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroradiology</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="873" to="888" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Aur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Simone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">O</forename><surname>Hustu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="272" to="281" />
			<date type="published" when="1971">1971</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995)</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Silverman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Declerck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Gelber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2247" to="2256" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Long-term results of large prospective trials in childhood acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schrappe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Camitta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Pui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2193" to="2194" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Childhood ALL Collaborative Group. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials</title>
		<author>
			<persName><forename type="first">M</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gaynon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1798" to="1809" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia/ lymphoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Vagace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>De La Maya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Caceres-Marzal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gonzalez De Murillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gervasini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Rev Oncol Hematol</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="274" to="286" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Neurocognitive effects of treatment for childhood cancer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Butler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Haser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ment Retard Dev Disabil Res Rev</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="184" to="191" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Pui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Leung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">349</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="640" to="649" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Impact of chemotherapy for childhood leukemia on brain morphology and function</title>
		<author>
			<persName><forename type="first">M</forename><surname>Genschaft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Huebner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Plessow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page">e78599</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Lange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Bostrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Cherlow</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children&apos;s Cancer Group</title>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="825" to="833" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>Children&apos;s Cancer Group</note>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Bostrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Sensel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Sather</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children&apos;s Cancer Group</title>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="3809" to="3817" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Children&apos;s Cancer Group</note>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Hutchinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Gaynon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sather</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Children&apos;s Cancer Group/Children&apos;s Oncology Group. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: longterm follow-up of patients treated on Children&apos;s Cancer Group Trial 1881</title>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1790" to="1797" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">N</forename><surname>Hagedorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Acquaviva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fronkova</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of &quot;isolated&quot; and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group</title>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="4022" to="4029" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>Resistant Disease Committee of the International BFM study group</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Waters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Leighton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="issue">9757</biblScope>
			<biblScope unit="page" from="2009" to="2017" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials</title>
		<author>
			<persName><forename type="first">S</forename><surname>Krishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Moorman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="450" to="459" />
			<date type="published" when="1985">1985-2001. 2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Holland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">V</forename><surname>Castro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Alexander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="638" to="649" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS</title>
		<author>
			<persName><forename type="first">G</forename><surname>Cario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Izraeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Teichert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">30</biblScope>
			<biblScope unit="page" from="4813" to="4820" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Interleukin-15 is an autocrine/ paracrine viability factor for cutaneous T-cell lymphoma cells</title>
		<author>
			<persName><forename type="first">U</forename><surname>D Öbbeling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dummer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Laine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Potoczna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Z</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Burg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="252" to="258" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Z</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kamarashev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dummer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Burg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2778" to="2783" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Expression of interleukin 15 in primary adult acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="387" to="392" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">301</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="393" to="403" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Interleukin-15 enhances cellular proliferation and upregulates CNS homing molecules in pre-B acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yousafzai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="3116" to="3127" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">NK cell receptors</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Lanier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="359" to="393" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Controlling natural killer cell responses: integration of signals for activation and inhibition</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">O</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Peterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rajagopalan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="227" to="258" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">A potential role for interleukin-15 in the regulation of human natural killer cell survival</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Carson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Fehniger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Haldar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="937" to="943" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Fehniger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="3633" to="3638" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Interleukin 15: biology and relevance to human disease</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Fehniger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Caligiuri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="14" to="32" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Carson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Giri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Lindemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">180</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1395" to="1403" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dubois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="721" to="727" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Role of interleukin-15 in the development of human CD561 natural killer cells from CD341 hematopoietic progenitor cells</title>
		<author>
			<persName><forename type="first">E</forename><surname>Mr Ózek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Caligiuri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="2632" to="2640" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Szczepanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Szajnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Welsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Foon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Whiteside</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boyiadzis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol Immunother</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="73" to="79" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Tian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytokine</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="128" to="136" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Sutherland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rabinovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Chalupny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Brawand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cosman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1313" to="1319" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Substrateadhering lymphoid cells show impaired tumorigenicity and increased immunogenicity</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hochman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eshel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">290</biblScope>
			<biblScope unit="issue">5803</biblScope>
			<biblScope unit="page" from="248" to="249" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Cell adhesiveness is related to tumorigenicity in malignant lymphoid cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hochman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mador</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Gottesman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Shearer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Okon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Biol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1282" to="1288" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
	<note>Pt 1</note>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<title level="m" type="main">Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs)</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Bock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Knorr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Kaufman</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Vis Exp</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page">e50337</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46</title>
		<author>
			<persName><forename type="first">N</forename><surname>Bloushtain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Qimron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bar-Ilan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">173</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="2392" to="2401" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rosental</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Horlacher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Proteome Res</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="712" to="720" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cerwenka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Bakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mcclanahan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="721" to="727" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44</title>
		<author>
			<persName><forename type="first">B</forename><surname>Rosental</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brusilovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Hadad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="5693" to="5702" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">An experimental model for infiltration of malignant lymphoma to the eye and brain</title>
		<author>
			<persName><forename type="first">N</forename><surname>Assaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hasson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hoch-Marchaim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virchows Arch</title>
		<imprint>
			<biblScope unit="volume">431</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="459" to="467" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Entry routes of malignant lymphoma into the brain and eyes in a mouse model</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hochman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Assaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Deckert-Schl Üter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">D</forename><surname>Wiestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pe</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="5242" to="5247" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Optic nerve head infiltration in acute leukemia in children: an indication for emergency optic nerve radiation therapy</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kaikov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Pediatr Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="101" to="104" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Orbital and ocular manifestations of acute childhood leukemia: clinical and statistical analysis of 180 patients</title>
		<author>
			<persName><forename type="first">V</forename><surname>Russo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">U</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Querques</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Delle</forename><surname>Noci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="619" to="623" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">A novel B cell precursor ALL cell line (018Z) with prominent neurotropism and isolated CNS leukemia in a NOD/SCID/huALL xenotransplantation model</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Eckhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Queudeville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Debatin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Meyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="652" to="652" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice</title>
		<author>
			<persName><forename type="first">U</forename><surname>Siegler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Kalberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nowbakht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sendelov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Meyer-Monard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wodnar-Filipowicz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2215" to="2222" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Shultz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Lyons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Burzenski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">174</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="6477" to="6489" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Eckhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Queudeville</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="206" to="217" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Mer tyrosine kinase promotes the survival of t(1;19) positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pfeiffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Strube</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="820" to="830" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jeha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Raimondi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1406" to="1409" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>De Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Ladner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="2497" to="2503" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Moretta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bottino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vitale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="197" to="223" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">The role of the NKG2D receptor for tumor immunity</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Coudert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Held</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Cancer Biol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="333" to="343" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Promiscuity and the single receptor: NKG2D</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Eagle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Trowsdale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="737" to="744" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes</title>
		<author>
			<persName><forename type="first">A</forename><surname>Shibuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hannum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="573" to="581" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Torelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Peragine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Raponi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1248" to="1254" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Thermal-and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hedlund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Nagaeva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kargl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Baranov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mincheva-Nilsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">e16899</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Soluble ULBP suppresses natural killer cell activity via downregulating NKG2D expression</title>
		<author>
			<persName><forename type="first">H</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cosman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Choi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Immunol</title>
		<imprint>
			<biblScope unit="volume">239</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="22" to="30" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Both mature KIR1 and immature KIR-NK cells control pediatric acute B-cell precursor leukemia in NOD. Cg-Prkdcscid IL2rgtmWjl/Sz mice</title>
		<author>
			<persName><forename type="first">A</forename><surname>K Übler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Woiterski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Witte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="3914" to="3923" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Determinants of antileukemia effects of allogeneic NK cells</title>
		<author>
			<persName><forename type="first">W</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Iyengar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Turner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="644" to="650" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ruggeri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Capanni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Urbani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">295</biblScope>
			<biblScope unit="issue">5562</biblScope>
			<biblScope unit="page" from="2097" to="2100" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ruggeri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mancusi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Burchielli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood Cells Mol Dis</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="84" to="90" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T-and B-cell depleted grafts in children</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Pfeiffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Feuchtinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Teltschik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1381" to="1388" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Bao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="98" to="105" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL</title>
		<author>
			<persName><forename type="first">L</forename><surname>Oevermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">U</forename><surname>Michaelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mezger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="2744" to="2747" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells</title>
		<author>
			<persName><forename type="first">F</forename><surname>Fei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>George</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="788" to="797" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands</title>
		<author>
			<persName><forename type="first">L</forename><surname>Jardine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hambleton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bigley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">N</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Collin</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="167" to="173" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients</title>
		<author>
			<persName><forename type="first">N</forename><surname>Peragine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Torelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mariglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol Immunother</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="201" to="211" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity</title>
		<author>
			<persName><forename type="first">P</forename><surname>Satwani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bavishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Saha</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcyt.2014.03.008</idno>
	</analytic>
	<monogr>
		<title level="j">Cytotherapy</title>
		<imprint/>
	</monogr>
	<note>published online May 20, 2014 ahead of print</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Fo à R. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Torelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Guarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Maggio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Alfieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vitale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="785" to="792" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Almalte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Samarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iannello</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1323" to="1328" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Zirngibl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dorneburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1050" to="1061" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Rapid engraftment of human ALL in NOD/SCID mice involves deficient apoptosis signaling</title>
		<author>
			<persName><forename type="first">M</forename><surname>Queudeville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Seyfried</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Eckhoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">e364</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
